Nina Khanna Selected Research

8-hydroxyserrulat-14-en-19-oic acid

1/2013

Antimicrobial properties of 8-hydroxyserrulat-14-en-19-oic acid for treatment of implant-associated infections.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nina Khanna Research Topics

Disease

26	Infections 04/2022 - 02/2008
6	Communicable Diseases (Infectious Diseases) 01/2022 - 12/2012
5	Candidemia 10/2021 - 01/2017
5	Graft vs Host Disease (Graft-Versus-Host Disease) 10/2020 - 02/2008
3	COVID-19 11/2021 - 01/2020
3	Mycoses (Diseases, Fungus) 10/2020 - 07/2011
3	Aspergillosis 01/2016 - 04/2015
2	Neoplasms (Cancer) 01/2021 - 12/2015
2	Acute Kidney Injury (Acute Renal Failure) 01/2020 - 02/2004
2	Sudden Infant Death (SID) 05/2018 - 02/2008
2	Progressive Multifocal Leukoencephalopathy 10/2011 - 05/2009
2	HIV Infections (HIV Infection) 04/2004 - 02/2004
1	Urinary Tract Infections (Urinary Tract Infection) 01/2022
1	Nocardia Infections 01/2022
1	Pneumonia (Pneumonitis) 01/2022
1	Central Nervous System Infections (Central Nervous System Infection) 01/2022
1	ST Elevation Myocardial Infarction 02/2021
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2021
1	Clinical Deterioration 01/2021
1	Pseudomonas Infections 07/2020
1	Gram-Negative Bacterial Infections 06/2020
1	Cross Infection (Nosocomial Infection) 06/2020
1	Leukemia 03/2020
1	Soft Tissue Infections 02/2020
1	Aplastic Anemia (Anemia, Hypoplastic) 01/2020
1	Heart Diseases (Heart Disease) 01/2020
1	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 01/2020
1	Inflammation (Inflammations) 01/2020
1	Septic Shock (Toxic Shock Syndrome) 01/2020
1	Virus Diseases (Viral Diseases) 01/2020
1	Bacterial Infections (Bacterial Infection) 12/2018
1	Paramyxoviridae Infections (Parainfluenza) 05/2018
1	Toxoplasmosis 01/2018
1	Mucositis 01/2018
1	Invasive Candidiasis 03/2016
1	Candidiasis (Moniliasis) 03/2016
1	Esophagitis 01/2016
1	Invasive Fungal Infections 01/2016
1	Residual Neoplasm 12/2015

Drug/Important Bio-Agent (IBA)

9	Anti-Bacterial Agents (Antibiotics)IBA 04/2022 - 08/2014
5	AntigensIBA 11/2021 - 02/2008
5	Pharmaceutical PreparationsIBA 10/2021 - 10/2008
3	Daptomycin FDA Link 01/2021 - 07/2011
3	Antiviral Agents (Antivirals)IBA 01/2021 - 12/2015
2	AntibodiesIBA 11/2021 - 10/2011
2	EpitopesIBA 11/2021 - 06/2011
2	Immunoglobulin G (IgG)IBA 10/2020 - 10/2011
2	EnzymesIBA 01/2020 - 01/2020
2	Ribavirin (Virazole)FDA LinkGeneric 05/2018 - 02/2008
2	Intravenous Immunoglobulins (IVIG)FDA Link 05/2018 - 02/2008
2	Proteins (Proteins, Gene)FDA Link 03/2016 - 06/2011
2	RNA (Ribonucleic Acid)IBA 01/2016 - 10/2008
1	Rituximab (Mabthera)FDA Link 01/2021
1	Cytostatic AgentsIBA 01/2021
1	Fluorouracil (Carac)FDA LinkGeneric 01/2021
1	tocilizumab (atlizumab)FDA Link 01/2021
1	CefiderocolIBA 06/2020
1	CytokinesIBA 01/2020
1	Acetates (Acetic Acid Esters)FDA Link 01/2020
1	AminoglycosidesIBA 01/2020
1	C-Reactive ProteinIBA 01/2020
1	GlycopeptidesIBA 01/2020
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2020
1	NitroimidazolesIBA 01/2020
1	Cytochrome P-450 CYP3AIBA 01/2020
1	Lopinavir FDA Link 01/2020
1	Vancomycin FDA LinkGeneric 12/2018
1	LipopeptidesIBA 10/2018
1	Fluconazole (Zonal)FDA LinkGeneric 01/2018
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2017
1	SilverIBA 04/2016
1	LectinsIBA 03/2016
1	Mannose-Binding Lectin (Mannan-Binding Lectin)IBA 03/2016
1	Immunologic Factors (Immunomodulators)IBA 01/2016
1	Biocompatible Materials (Biomaterials)IBA 01/2016
1	Interleukin-17 (Interleukin 17)IBA 01/2016
1	PolymersIBA 01/2016
1	Protein Isoforms (Isoforms)IBA 12/2015

Therapy/Procedure

7	Therapeutics 04/2022 - 02/2004
6	Transplantation 01/2022 - 02/2008
5	Cell Transplantation 01/2022 - 05/2018
5	Hematopoietic Stem Cell Transplantation 12/2018 - 09/2010
4	Highly Active Antiretroviral Therapy (HAART) 01/2016 - 02/2004
3	Length of Stay 04/2022 - 02/2020
3	Organ Transplantation 01/2021 - 10/2020
3	Catheters 01/2018 - 08/2014
3	Culture Diffusion Chambers 04/2016 - 07/2011
2	Critical Care (Surgical Intensive Care) 01/2021 - 03/2016
1	Kidney Transplantation 01/2022
1	Percutaneous Coronary Intervention 02/2021
1	Artificial Respiration (Mechanical Ventilation) 01/2021
1	Liver Transplantation 10/2020
1	Duration of Therapy 07/2020
1	Patient Readmission 04/2020
1	Total Parenteral Nutrition 01/2020
1	Central Venous Catheters 01/2020
1	Parenteral Nutrition 01/2018
1	Drug Therapy (Chemotherapy) 01/2016
1	Precision Medicine 01/2016
1	Stem Cell Transplantation 12/2015